Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Replacing the current standard of care for urothelial carcinoma

Despite platinum-based chemotherapy including cisplatin and carboplatin being the standard of care for patients with urothelial carcinoma, a sizable proportion of patients relapse within a few months after treatment. Robert J. Jones, MD, PhD, University of Glasgow & Beatson West of Scotland Cancer Centre, Glasgow, UK, gives an overview of current strategies to overcome this barrier. Maintenance avelumab, an anti-PD-L1 monoclonal antibody, has demonstrated efficacy in patients when given after chemotherapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.